The OLE data is incrementally positive for safety but does not salvage the failed PALISADE-3 randomized trial. The stock's next catalyst is PALISADE-4 topline data in Q2 2026, a binary event that will determine whether fasedienol has a viable path to an NDA. Monitor for PALISADE-4 results and any financing needs given the small market cap.
VTGN drugs
VTGN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $0.6200entry
- T+1 · 6mo ago +6.45%α +5.88% · $0.6600
- T+5 · 6mo ago −3.23%α −3.30% · $0.6000
- T+20 · 5mo ago −12.90%α −11.18% · $0.5400
- T+60 · 3mo ago −54.23%α −58.61% · $0.2838
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vistagen announced preliminary positive safety and exploratory efficacy data from the open-label extension (OLE) of its PALISADE-3 Phase 3 study of fasedienol for social anxiety disorder. The OLE data showed fasedienol was well-tolerated over up to 12 months of as-needed use, with clinically relevant improvements on anxiety scales over four months. However, the randomized, placebo-controlled portion of PALISADE-3 failed its primary endpoint in December 2025, so this open-label data does not change the drug's regulatory path and the stock's binary risk profile remains tied to the upcoming PALISADE-4 topline results.
Key Facts
- PALISADE-3 OLE safety data (n=341): fasedienol well-tolerated up to 12 months, 2.6% discontinuation rate due to AEs, no drug-related SAEs.
- Exploratory efficacy: LSAS mean improvement of 25.4 points at Month 4 (n=228, 56% had ≥20-point improvement); SPIN mean improvement of 12.4 points at Month 4 (n=228, 55% had ≥10-point improvement).
- The randomized, double-blind portion of PALISADE-3 failed its primary endpoint in December 2025, no treatment difference vs placebo on SUDS.
- PALISADE-4 topline data expected in Q2 2026; Phase 2 Repeat Dose Study topline expected in Q3 2026.
- Market cap is ~$27M with 0% analyst bullish consensus (7 Hold, 3 Sell/Strong Sell).
Financial Impact
No financial figures disclosed in filing. Company is pre-revenue clinical-stage biotech with $27M market cap.
Risk Factors
- PALISADE-4 may also fail to meet its primary endpoint, mirroring PALISADE-3's failure.
- Company may need to raise capital to fund ongoing operations, causing dilution.
- Even if PALISADE-4 succeeds, FDA may require additional trials before accepting an NDA.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-033883 |
| Document: vtgn-20260512.htm | 0001628280-26-033883 |
| Document: 0001628280-26-033883-index-headers.html | 0001628280-26-033883 |
| Document: 0001628280-26-033883-index.html | 0001628280-26-033883 |
| Document: 0001628280-26-033883.txt | 0001628280-26-033883 |
Track record
21 reports on VTGN
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
- Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers